Maxim Group analyst Jason McCarthy downgrades VistaGen Therapeutics (NASDAQ:VTGN) from Buy to Hold.
Truist Securities Maintains Buy on NuVasive, Lowers Price Target to $58
Truist Securities analyst Richard Newitter maintains NuVasive (NASDAQ:NUVA) with a Buy and lowers the price target from $63 to $58.